Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.: Social discussions and analytics

SGLT2 Inhibitors for Kidney Disease: Clinical Insights and Benefits

This Harvard Medical School Continuing Education video explores how SGLT2 inhibitors like canagliflozin and dapagliflozin protect the kidneys, review key trial findings, and discuss updated guidelines, highlighting…

Harvard Medical School Continuing Education · Apr 7, 2022 41,298 views

Impact of Salt Substitutes on Cardiovascular Health

Dr. Bruce Neal, a leading cardiologist, explores the cardiovascular implications of low sodium and high potassium diets. He presents findings from the 2021 SSASS Study, which involved 20,995 high-risk patients assessing…

MARKUS at HOMe · Oct 15, 2021 687 views

Updates on Cardiological Research: Key Findings and Implications

The video provides a weekly update on cardiovascular updates in prominent journals. This episode highlights significant articles including findings on Canagliflozin as a promising treatment for patients with type 2…

CardioLearning · Apr 24, 2019 408 views

Impact of SGLT2 Inhibitors on Kidney Health in Diabetes Patients

In this podcast, John Mandrola MD discusses SGLT2 inhibitors, their effects on chronic kidney disease, and highlights significant trial outcomes showing a 30% lower risk of severe kidney issues with Canagliflozin. A…

Medscape · Mar 27, 2024 12 views

Dr. Yasir Dar

@Yasirdar085 · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | New England Journal of Medicine https://t.co/05kyGRdOtI

Dec 9, 2024 · 1 like · 353 followers View post →

Sri Lekha Tummalapalli, MD, MBA

@LTummalapalli · X

@amitksvs References here: CREDENCE: https://t.co/HKhHT9kFqp FIDELIO-DKD: https://t.co/dXu1ZlqTjM SONAR: https://t.co/ELyfrCc3cD FLOW: https://t.co/qTVwBT392F

Oct 25, 2024 · 2,317 followers View post →

Joyce Bwombengi

@kemuntoMD · X

RT @cardiomet_CE: 35) In the #SGLT2i and #MRAtrials, pts w/ #T2D who received active treatment had ⬇️ in #UACR:

Jun 10, 2024 · 3 shares · 1,082 followers View post →

cardio-met

@cardiomet_CE · X

24a) @goKIDIGO 3.7 Sodium-glucose cotransporter-2 inhibitors (#SGLT2i) Some of the trials that support the use of SGLT2i in this population are: #CREDENCE

May 20, 2024 · 1 like · 4,157 followers View post →

腎臓病薬剤師ネットワーク(腎Net)

@CKD_pharmacist · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | New England Journal of Medicine #67jds https://t.co/tnkL2gjbKe

May 17, 2024 · 1 like · 1,177 followers View post →

@CKD_ce

@ckd_ce · X

24a) @goKIDIGO 3.7 Sodium-glucose cotransporter-2 inhibitors (#SGLT2i) Some of the trials that support the use of SGLT2i in this population are: #CREDENCE

May 7, 2024 · 2 likes · 2,636 followers View post →

SABOURETCardiologist

@SABOURETCardio · X

https://t.co/3BOGFk8szL #SGLT2i

Mar 14, 2024 · 3 likes · 31,150 followers View post →

SABOURETCardiologist

@SABOURETCardio · X

The new entry in France

Dec 27, 2023 · 5 likes · 31,150 followers View post →

Science Collected

@ScienceCollect1 · X

15/ For more details on the data, check out the links below:

Sep 7, 2023 · 124 followers View post →

Ahmed Mohsen

@drahmedmohsen85 · X

RT @cardiomet_CE: 35) In the #SGLT2i and #MRAtrials, pts w/ #T2D who received active treatment had ⬇️ in #UACR:

May 31, 2023 · 3 shares · 22,937 followers View post →

JorgeEdoChava75

@QicenoJorge · X

RT @cardiomet_CE: 35) In the #SGLT2i and #MRAtrials, pts w/ #T2D who received active treatment had ⬇️ in #UACR:

May 31, 2023 · 3 shares · 998 followers View post →

cardio-met

@cardiomet_CE · X

35) In the #SGLT2i and #MRAtrials, pts w/ #T2D who received active treatment had ⬇️ in #UACR:

May 31, 2023 · 4 likes · 3 shares · 4,157 followers View post →

@CKD_ce

@ckd_ce · X

35) In the #SGLT2i and #MRA trials, pts w/ #T2D who received active treatment had ⬇️ in #UACR:

May 18, 2023 · 1 like · 2,636 followers View post →

Hayaan Kamran

@kamran_hayaan · X

RT @cardiomet_CE: 16) #SGLT2i also 1st line for glycemic control (2nd line for proteinuria) w/eGFR >20. Many clinical trials have shown imp…

Apr 20, 2023 · 2 shares · 441 followers View post →

Ahmed Mohsen

@drahmedmohsen85 · X

RT @cardiomet_CE: 16) #SGLT2i also 1st line for glycemic control (2nd line for proteinuria) w/eGFR >20. Many clinical trials have shown imp…

Apr 20, 2023 · 2 shares · 22,937 followers View post →

cardio-met

@cardiomet_CE · X

16) #SGLT2i also 1st line for glycemic control (2nd line for proteinuria) w/eGFR >20. Many clinical trials have shown improved kidney & #CV outcomes (#DAPA_CKD #EMPA_REG_OUTCOME #EMPA_KIDNEY #CANVAS #CREDENCE, below), some even in pts w/o diabetes.

Apr 20, 2023 · 3 likes · 2 shares · 4,157 followers View post →

@CKD_ce

@ckd_ce · X

16) #SGLT2i also 1st line for glycemic control (2nd line for proteinuria) w/eGFR >20. Many clinical trials have shown improved kidney & #CV outcomes (#DAPA_CKD #EMPA_REG_OUTCOME #EMPA_KIDNEY #CANVAS #CREDENCE, below), some even in pts w/o diabetes.

Apr 11, 2023 · 2 likes · 2,636 followers View post →

cardio-met

@cardiomet_CE · X

25) #SGLT2i’s are recommended in patients with #T2D and #CKD with an #eGFR of ≥20 mL/min regardless of #HbA1c. In #CREDENCE, #canagliflozin reduced primary & renal-specific composite outcomes & was consistent across subgroups.

Mar 15, 2023 · 1 like · 4,157 followers View post →

@CKD_ce

@ckd_ce · X

25) #SGLT2i’s are recommended in patients with #T2D and #CKD with an #eGFR of ≥20 mL/min regardless of #HbA1c. In #CREDENCE, #canagliflozin reduced primary & renal-specific composite outcomes & was consistent across subgroups.

Jan 11, 2023 · 3 likes · 2,636 followers View post →

Madelayne Mejía

@MejiaMadelayne · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Dec 5, 2022 · 2 followers View post →

Abhishek

@aksrulz13 · X

RT @drdschwartzmd: This study showed that in patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascula…

Dec 2, 2022 · 1 share · 623 followers View post →

Abhishek

@aksrulz13 · X

RT @drdschwartzmd: 4) CREDENCE: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy The first primary CKD study to show th…

Dec 2, 2022 · 1 share · 623 followers View post →

Daniel Schwartz, MD

@drdschwartzmd · X

This study showed that in patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group. https://t.co/MuDV2LvqO0

Dec 2, 2022 · 2 likes · 1 share · 1,085 followers View post →

Daniel Schwartz, MD

@drdschwartzmd · X

4) CREDENCE: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy The first primary CKD study to show that an SGLT2i can reduce kidney outcomes in patients with diabetes and kidney disease. https://t.co/WjhQAKeJbQ

Dec 2, 2022 · 3 likes · 1 share · 1,085 followers View post →

Daniel Schwartz, MD

@drdschwartzmd · X

We know from CREDENCE, DAPA-CKD and EMPA-KIDNEY that SGLT2i + ACEi or ARB (aka RAASi) is safe and effective at reducing renal/CV endpoints https://t.co/qBwox3fWyp https://t.co/IlxMKlDJpB https://t.co/1jF5YfzLHz

Nov 29, 2022 · 3 likes · 1 share · 1,085 followers View post →

Anthony Chan Yon Quan

@anthonychanmd · X

RT @edgarvlermamd: CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to curre…

Nov 7, 2022 · 41 shares · 34 followers View post →

Carlos Maiorana

@MaioranaCarlos · X

@jpcostabel @secardiologia @SENefrologia @SVNefro @jlgorriz @nephondemand @CristobMorales @SIAC_cardio @AmbrizMau @mvaduganathan @brendonneuen @JuliaSellerm @Dr_Manito @purviparwani @rafavidalperez @jorgericof Miremos los resultados con CANA en 100% DM2 https://t.co/iFr29uSViz

Nov 5, 2022 · 1 like · 345 followers View post →

Monmon

@NoOtherMon · X

RT @ckd_ce: 7) This recommendation is based on strong evidence that #SGLT2i reduce #CKD progression, #HF, and #ASCVD risk in patients with…

Nov 3, 2022 · 3 shares · 3,411 followers View post →

Cher ባንቄ

@tsebank · X

RT @ckd_ce: 8) These trials enrolled pts w/ #albuminuria: #CREDENCE: ACR >/=300 mg/g #DAPA_CKD: ACR >/=200 mg/g & showed significant benefi…

Oct 23, 2022 · 1 share · 49 followers View post →

Cher ባንቄ

@tsebank · X

RT @ckd_ce: 7) This recommendation is based on strong evidence that #SGLT2i reduce #CKD progression, #HF, and #ASCVD risk in patients with…

Oct 23, 2022 · 3 shares · 49 followers View post →

Kananura Keneth

@kkananura · X

RT @ckd_ce: 7) This recommendation is based on strong evidence that #SGLT2i reduce #CKD progression, #HF, and #ASCVD risk in patients with…

Oct 19, 2022 · 3 shares · 4,230 followers View post →

@CKD_ce

@ckd_ce · X

8) These trials enrolled pts w/ #albuminuria: #CREDENCE: ACR >/=300 mg/g #DAPA_CKD: ACR >/=200 mg/g & showed significant benefit for composite outcomes/EPs:

Oct 18, 2022 · 7 likes · 1 share · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

7) This recommendation is based on strong evidence that #SGLT2i reduce #CKD progression, #HF, and #ASCVD risk in patients with #T2D and CKD #VisualAbstract by @brendonneuen @whatsthegfr #CREDENCE

Oct 18, 2022 · 8 likes · 3 shares · 2,636 followers View post →

American Society of Pediatric Nephrology

@ASPNeph · X

RT @AcidosisTubular:

Sep 11, 2022 · 1 share · 10,139 followers View post →

ATR

@AcidosisTubular · X

Sep 11, 2022 · 1 like · 1 share · 7,134 followers View post →

鯵ゼミ_Journal Club

@AJSR_since2005 · X

#099 Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019;380:2295-306. CREDENCE試験 CKDを合併した2型糖尿病で、カナグリフロジンはプラセボと比較して、腎関連の複合エンドポイントを改善する

Jul 23, 2022 · 6 followers View post →

たけちゃん

@nitrotake · X

カナグリフロジンの適応追加がきっかけになった臨床試験 https://t.co/aiv1tjD5H7

Jun 21, 2022 · 1 like · 1,441 followers View post →

José David

@josedacarrillo · X

1. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med [Internet]. 2019;380(24):2295–306. Available from: https://t.co/5yirfAYxyC

May 10, 2022 · 167 followers View post →

Lizbeth Armijos

@k7f42vvz4s · X

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy - Medical English https://t.co/Ms5lHMwBQ6

Apr 13, 2022 · 1 like · 2 followers View post →

Shinya

@uPkKLnbJUWCCPBL · X

RT @medical_910: #CardioJapan #NEJM https://t.co/jCrlOacHwe 一言でいうと　2型糖尿病（アルブミン尿＋）の患者にカナグリフロジン投与したらアウトカムがめちゃくちゃ改善した件ｗｗｗ N Engl J Med. 2019…

Mar 30, 2022 · 2 shares · 8,378 followers View post →

おれんじ色

@orangeiro7 · X

RT @IshiyakuApp: カナグル主要試験【CREDENCE試験】アルブミン尿を有する慢性腎臓病（30<eGFR<90）を伴う2型DMに対して、プラセボと比較して、カナグリフロジン100mgとプラセボを比較して、追跡期間中央値2.62年における腎不全および心血管イベ…

Mar 13, 2022 · 1 share · 1,811 followers View post →

イシヤク | 医師向け薬剤比較アプリ

@IshiyakuApp · X

カナグル主要試験【CREDENCE試験】アルブミン尿を有する慢性腎臓病（30<eGFR<90）を伴う2型DMに対して、プラセボと比較して、カナグリフロジン100mgとプラセボを比較して、追跡期間中央値2.62年における腎不全および心血管イベントの発生リスクを30%有意に低下させた https://t.co/Z5MWU7C2se

Mar 13, 2022 · 3 likes · 1 share · 19,157 followers View post →

@CKD_ce

@ckd_ce · X

6) #Canagliflozin in the CREDENCE trial (

Jan 19, 2022 · 12 likes · 2,636 followers View post →

Anace Pastor ✨️ Renalis

@anace710 · X

RT @ISNeducation: 17/27 In 2018, the results of the CREDENCE study were presented during the #ISNWCN. We had a new class of medication (SGL…

Dec 11, 2021 · 2 shares · 1,899 followers View post →

ISN Education

@ISNeducation · X

17/27 In 2018, the results of the CREDENCE study were presented during the #ISNWCN. We had a new class of medication (SGLT2-i) to treat DM CKD after a long period without innovations. Check DOI: 10.1056/NEJMoa1811744 #ISNTweetorial https://t.co/fD8RHnmMK6

Dec 11, 2021 · 5 likes · 2 shares · 10,498 followers View post →

Evan Zeitler

@LittleBigGloms · X

RT @kidney_boy: @_GoozNews The entire article never mentions that this one of only drugs to reduce total mortality. Shameful. 2202 people…

Dec 10, 2021 · 1 share · 905 followers View post →

Joel M. Topf, MD FACP

@kidney_boy · X

@_GoozNews The entire article never mentions that this one of only drugs to reduce total mortality. Shameful. 2202 people, 2.6 years 11 cases of DKA In that time there was 30 fewer CV deaths & 60 fewer people on dialysis with Cana https://t.co/A3M8K4jIda https://t.co/YLMGX1CbCX

Dec 10, 2021 · 6 likes · 1 share · 63,295 followers View post →

Katchin Diabetes Solution

@KachinDiabetes · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/ZCaZLPAWcL

Nov 15, 2021 · 55 followers View post →

Xavier Sabino

@pacosabino · X

RT @Diabetes_SEMI: Articulo que refuerza el tratamiento de la #diabetes En pacientes con diabetes tipo 2 y enfermedad renal, el riesgo de…

Nov 13, 2021 · 30 shares · 349 followers View post →

cardio-met

@cardiomet_CE · X

40) CREDENCE (DOI: 10.1056/NEJMoa1811744) showed us that canagliflozin in patients with T2D and albuminuric CKD significantly outperformed placebo on renal outcomes. The RR of the renal-specific composite of ESRD, a doubling of the creat level, or death from renal causes . . .

Sep 2, 2021 · 3 likes · 4,157 followers View post →

UKCPA Diabetes & Endocrinology Committee

@UKCPADiabetes · X

RT @cardiomet_CE: Now moving on to #CKD @brendonneuen presented this image Projected from the CREDENCE Trial (https://t.co/n3Wg4N765o)…

Jul 9, 2021 · 4 shares · 1,068 followers View post →

GoggleDocs

@GoggleDocs · X

RT @cardiomet_CE: Now moving on to #CKD @brendonneuen presented this image Projected from the CREDENCE Trial (https://t.co/n3Wg4N765o)…

Jul 8, 2021 · 4 shares · 3,654 followers View post →

Kevin Fernando

@drkevinfernando · X

RT @cardiomet_CE: Now moving on to #CKD @brendonneuen presented this image Projected from the CREDENCE Trial (https://t.co/n3Wg4N765o)…

Jul 8, 2021 · 4 shares · 5,134 followers View post →

Dr Amar Puttanna

@AmarPut · X

RT @cardiomet_CE: Now moving on to #CKD @brendonneuen presented this image Projected from the CREDENCE Trial (https://t.co/n3Wg4N765o)…

Jul 8, 2021 · 4 shares · 3,620 followers View post →

James Tollitt

@JTollitt · X

@bmj_latest @will_s_t https://t.co/GLHnSOOxDq

May 11, 2021 · 654 followers View post →

Joel M. Topf, MD FACP

@kidney_boy · X

@steve__72 @6catsCatholic @sbABetterLeader @AstraZenecaUS The data on post transplant is soft. The CKD data is compelling and strong. Best (CKD, not a transplant) studies to look are CREDENCE (all diabetics): https://t.co/A3M8K4jIda and DAPA-CKD (1/3rd non-diabetes): https://t.co/OD19ytjLIZ https://t.co/kxPPPp44h0

Mar 15, 2021 · 1 like · 63,295 followers View post →

Nikolay Novitskiy

@novitskiynic · X

RT @drjohnm: Post-hoc studies always deserve caution but the main trial results were positive https://t.co/r9PGDd11Fq #SGLT2i continue to…

Feb 9, 2021 · 1 share · 2,432 followers View post →

John Mandrola, MD

@drjohnm · X

Post-hoc studies always deserve caution but the main trial results were positive https://t.co/r9PGDd11Fq #SGLT2i continue to impress. These are no longer just diabetic drugs. https://t.co/2ba6QXTOfF

Feb 9, 2021 · 7 likes · 1 share · 68,601 followers View post →

Juan Senior

@jsenior64 · X

https://t.co/ZNjPrBk67M

Jan 11, 2021 · 11,075 followers View post →

TS Roosevelt, MD, fka Gordon Pasha

@TSRooseveltRE · X

@LeiaRx @mikejohansenmd https://t.co/ra3lL6So51

Jan 5, 2021 · 898 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

@pabloange @goKDIGO That is a post hoc analysis of CREDENCE (subgroup analysis of patients with GFR < 30)

Nov 21, 2020 · 3 likes · 33,603 followers View post →

Miguel Cedeño

@MiguelCedenoC1 · X

https://t.co/gypbhQE94g

Nov 11, 2020 · 5 likes · 1 followers View post →

javier_jimenez98

@Jimenez98Javier · X

https://t.co/fisXSvINOI Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy Gilton Javier Jimenez Quezada. Medical English. Dr. John Moscoso. 4 "A"

Nov 4, 2020 · 5 likes · 6 followers View post →

Oladimeji Oki, MD

@TheRealDr_O · X

RT @UREssien: Inpatient Lesson of the Day 5: We went on SGLT2 inhibitor rounds today. Reminded the team of the successes of these diabetes…

Oct 17, 2020 · 2 shares · 622 followers View post →

Hennypenny!

@Hennype85026470 · X

RT @UREssien: Inpatient Lesson of the Day 5: We went on SGLT2 inhibitor rounds today. Reminded the team of the successes of these diabetes…

Oct 17, 2020 · 2 shares · 3,406 followers View post →

Utibe R. Essien, MD MPH

@UREssien · X

Inpatient Lesson of the Day 5: We went on SGLT2 inhibitor rounds today. Reminded the team of the successes of these diabetes? CHF? renal? drugs. Also of how great it is to work in a system where

Oct 17, 2020 · 13 likes · 2 shares · 23,885 followers View post →

Letaief

@hmidato · X

RT @edgarvlermamd: CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to curre…

Oct 6, 2020 · 6 shares · 370 followers View post →

Hot Science Balloon

@hotsciballoon · X

Nutshell #113: When compared to #placebo, the use of #canagliflozin in patients with type 2 #diabetes significantly reduced the risk for #cardiovascular or renal death, #dialysis, myocardial #infarction, and #stroke. Article: https://t.co/THaFYYhoLD #research #medicine #science https://t.co/GJ6QbvhoM3

Sep 29, 2020 · 1 like · 99 followers View post →

Jefferson Internal Medicine Residency Program

@JeffMedChiefs · X

The correct answer is D. Empagliflozin slows progression of CKD (Creedence Trial) and decreases HF Mort. (Empa-Reg). Weirdly enough Dapagliflozin even decreases HF mortality in those without DM (Dapa-HF)! https://t.co/uQgWHBCtOK https://t.co/OXfmH0xdNX https://t.co/ejiDl9xakh https://t.co/kOM3bZIjde

Sep 28, 2020 · 2,107 followers View post →

Showtime

@withspin · X

RT @IanJStewart3: @chungk1031 I’m a nephrologist, so the kidney studies are particularly interesting to me. CREDENCE. https://t.co/mRoOlfX…

Sep 3, 2020 · 2 shares · 3,587 followers View post →

Kevin K. Chung, MD

@chungk1031 · X

RT @IanJStewart3: @chungk1031 I’m a nephrologist, so the kidney studies are particularly interesting to me. CREDENCE. https://t.co/mRoOlfX…

Sep 3, 2020 · 2 shares · 14,107 followers View post →

Ian J. Stewart

@IanJStewart3 · X

@chungk1031 I’m a nephrologist, so the kidney studies are particularly interesting to me. CREDENCE. https://t.co/mRoOlfX0hm

Sep 3, 2020 · 2 likes · 2 shares · 160 followers View post →

Kam Kalantar-Zadeh, MD, MPH, PhD

@kamkalantar · X

RT @kamkalantar: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE) Trial - American College of Cardiology http…

Aug 25, 2020 · 2 shares · 4,629 followers View post →

Zeeshan Khawaja. MD, FASN

@Zeekay225 · X

RT @kamkalantar: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE) Trial - American College of Cardiology http…

Aug 24, 2020 · 2 shares · 23 followers View post →

Kam Kalantar-Zadeh, MD, MPH, PhD

@kamkalantar · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE) Trial - American College of Cardiology https://t.co/riNu59kchc

Aug 24, 2020 · 11 likes · 2 shares · 4,629 followers View post →

Dr Anastasia Mihailidou FAHA FCSANZ FESC

@AnastasiaSMihai · X

@Heart_SCCT @DrMarthaGulati @JAMACardiology @lesleejshaw Congratulations everyone

Aug 22, 2020 · 1 like · 19,305 followers View post →

Eduardo.Osorio

@EduOsorio93 · X

RT @Diabetes_SEMI: Articulo que refuerza el tratamiento de la #diabetes En pacientes con diabetes tipo 2 y enfermedad renal, el riesgo de…

Jul 15, 2020 · 30 shares · 7 followers View post →

SABARINATH S MD,DM,PDF(Renal Tx),FASN,FISN

@sabarivenus · X

RT @edgarvlermamd: CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to curre…

Jul 9, 2020 · 1 share · 1,007 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to current standard of care ca. 2019 from @NEJM #VisualAbstract by @brendonneuen #Nephpearls

Jun 22, 2020 · 3 likes · 1 share · 33,603 followers View post →

Professor M Z Khalil

@mzkhalil · X

#Canagliflozin reduces heart failure in patients with T2-DM & CKD (#CREDENCE trial). | NEJM Another #SGLT2i success story! https://t.co/rRs3f5Pbgy https://t.co/Oq3URS9AGM

Jun 19, 2020 · 2,856 followers View post →

Andrea Van Hook

@ande818 · X

RT @CRForumUS: Congratulations to Dr. Kenneth Mahaffey on receiving a Top 10 Distinguished Clinical Research Achievement Award! Learn more…

Jun 19, 2020 · 1 share · 24 followers View post →

Clinical Research Forum

@CRForumUS · X

Congratulations to Dr. Kenneth Mahaffey on receiving a Top 10 Distinguished Clinical Research Achievement Award! Learn more about the study, "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy," in his Top 10 video @StanfordMed #TopTen https://t.co/FVqJt60vnp https://t.co/aClwTK74sq

Jun 19, 2020 · 3 likes · 1 share · 532 followers View post →

#Babyjonas2 ♥

@pamelitajonitas · X

RT @VictorPinoJr1: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy https://t.co/PmKRjwu73N vía @YouTube

Jun 18, 2020 · 2 shares · 754 followers View post →

Zulay Quintanilla S.

@ZuPiquisa · X

RT @VictorPinoJr1: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy https://t.co/PmKRjwu73N vía @YouTube

Jun 17, 2020 · 2 shares · 86 followers View post →

Victor Pino Jr.

@VictorPinoJr1 · X

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy https://t.co/PmKRjwu73N vía @YouTube

May 14, 2020 · 23 likes · 2 shares · 3 followers View post →

UC Irvine Kidney

@UCIkidney · X

RT @kamkalantar: #Canagliflozin and #Renal #Outcomes in Type 2 #Diabetes and #Nephropathy (#CREDENCE) #Trial Apr 22, 2020, Robin Lo, MD;…

Apr 30, 2020 · 5 shares · 1,774 followers View post →

Kam Kalantar-Zadeh, MD, MPH, PhD

@kamkalantar · X

RT @kamkalantar: #Canagliflozin and #Renal #Outcomes in Type 2 #Diabetes and #Nephropathy (#CREDENCE) #Trial Apr 22, 2020, Robin Lo, MD;…

Apr 28, 2020 · 5 shares · 4,629 followers View post →

Connie Rhee

@ConnieMRhee · X

RT @kamkalantar: #Canagliflozin and #Renal #Outcomes in Type 2 #Diabetes and #Nephropathy (#CREDENCE) #Trial Apr 22, 2020, Robin Lo, MD;…

Apr 28, 2020 · 5 shares · 830 followers View post →

Eduardo Baamonde

@ebaamonde · X

RT @kamkalantar: #Canagliflozin and #Renal #Outcomes in Type 2 #Diabetes and #Nephropathy (#CREDENCE) #Trial Apr 22, 2020, Robin Lo, MD;…

Apr 26, 2020 · 5 shares · 626 followers View post →

Kam Kalantar-Zadeh, MD, MPH, PhD

@kamkalantar · X

#Canagliflozin and #Renal #Outcomes in Type 2 #Diabetes and #Nephropathy (#CREDENCE) #Trial Apr 22, 2020, Robin Lo, MD; Kam Kalantar-Zadeh, MD; Connie @ConnieMRhee, MD. - American College of Cardiology https://t.co/Jfiyno7SSf

Apr 25, 2020 · 7 likes · 5 shares · 4,629 followers View post →

Khushbinder dhiman

@Khushbinder11 · X

RT @ACCinTouch: Read a new expert analysis on the Canagliflozin and Renal Outcomes in Type 2 #Diabetes and Nephropathy (CREDENCE) Trial: ht…

Apr 23, 2020 · 1 share · 246 followers View post →

American College of Cardiology

@ACCinTouch · X

Read a new expert analysis on the Canagliflozin and Renal Outcomes in Type 2 #Diabetes and Nephropathy (CREDENCE) Trial: https://t.co/siUXnFSnU3

Apr 22, 2020 · 7 likes · 1 share · 156,064 followers View post →

Clinical Research Forum

@CRForumUS · X

Congratulations to Dr. Kenneth Mahaffey on his Distinguished Clinical Research Achievement Award for his incredible study "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy" @StanfordMed #TopTen https://t.co/FVqJt60vnp

Apr 16, 2020 · 2 likes · 532 followers View post →

Travis Smith, D.O. FAAEM

@RosenelliEM · X

The CANVAS and CREDENCE trial both showed that patients with diabetes treated with canagliflozin experienced less cardiovascular events, and those in the CREDENCE trial had less kidney failure. https://t.co/LFZLnCKg8D https://t.co/WAiq5u3Pj7

Apr 14, 2020 · 5,104 followers View post →

Travis Smith, D.O. FAAEM

@RosenelliEM · X

This works w/ the effect of ACEi/ARB which inhibit vasoconstriction of the efferent arteriole; SGLT2i can still provide improvement in renal outcomes for diabetic kidney disease in pts on maximum doses of ACE inhibitor (which increases efferent flow). https://t.co/WAiq5u3Pj7

Apr 14, 2020 · 5,104 followers View post →

Letaief

@hmidato · X

RT @edgarvlermamd: CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to curre…

Apr 6, 2020 · 41 shares · 370 followers View post →

Anita at

@AnitaFanse80 · X

RT @edgarvlermamd: CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to curre…

Apr 1, 2020 · 41 shares · 294 followers View post →

UTSWIM JOURNALWATCH

@UTSWIMJW · X

Dr. Cody McCoy – Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://t.co/tP0zUZ7513

Mar 20, 2020 · 1 like · 383 followers View post →

Letaief

@hmidato · X

RT @edgarvlermamd: CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to curre…

Mar 13, 2020 · 1 share · 370 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to current standard of care ca. 2019 from @NEJM #VisualAbstract by @brendonneuen #Nephmadness 2️⃣

Mar 13, 2020 · 1 like · 1 share · 33,603 followers View post →

Srinivas Mahesh Prasad Nephrologist

@NephPrasad · X

RT @brendonneuen: Canagliflozin reduces the risk of kidney failure or death due to cardiovascular or kidney disease by 30% compared to curr…

Mar 2, 2020 · 269 shares · 959 followers View post →

Elena Cervantes

@Elena_Cervants · X

@askrenal @NephJC @cwgillihan Yes! A subgroup analysis of the CREDENCE trial shows that ~4% of the patients had, in fact, an eGFR < 30 mg/dL. Also, the patients were continued on canagliflozin treatment per protocol until initiation of dialysis or kidney transplantation. https://t.co/pXfakuS5Jw

Feb 27, 2020 · 1 like · 1,678 followers View post →

Doctor

@abmdoctor · X

RT @MelBreggs: 1/3-Day 8: Cardiology started an SGLT2 inhibitor on a patient for the first time. Thought it would be good to give a bri…

Feb 21, 2020 · 4 shares · 656 followers View post →

Ethical GmbH

@Ethicalgmbh · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://t.co/kxaKbKleSn #clinicalresearch #clinicaltrials #endpointadjudication #electronichealthrecords #clinicalstudies #digitalsignatures #patientengagement #pharmacovigilance #eclinical https://t.co/sHSSLOq5QK

Feb 21, 2020 · 488 followers View post →

Leesa Novotny

@DocLeesa · X

RT @MelBreggs: 1/3-Day 8: Cardiology started an SGLT2 inhibitor on a patient for the first time. Thought it would be good to give a bri…

Feb 17, 2020 · 4 shares · 34 followers View post →

Colin Gallagher

@clngallagher · X

RT @MelBreggs: 1/3-Day 8: Cardiology started an SGLT2 inhibitor on a patient for the first time. Thought it would be good to give a bri…

Feb 17, 2020 · 4 shares · 75 followers View post →

Michelle Fleshner

@MFleshner301 · X

RT @MelBreggs: 1/3-Day 8: Cardiology started an SGLT2 inhibitor on a patient for the first time. Thought it would be good to give a bri…

Feb 17, 2020 · 4 shares · 528 followers View post →

Melissa Bregger, MD, FACP

@MelBreggs · X

1/3-Day 8: Cardiology started an SGLT2 inhibitor on a patient for the first time. Thought it would be good to give a brief overview of CANVAS & CREDENCE Trials to review why an SGLT2i was started. CANVAS Trial: https://t.co/mfw2cI9buz CREDENCE Trial: https://t.co/2rGjYf92WQ

Feb 17, 2020 · 12 likes · 4 shares · 1,708 followers View post →

Blanca Dominguez

@blancadguezdpaz · X

@GustavoFdz @doctormacias https://t.co/K2KlwU7CgP No es tan nuevo pero espero sea de utilidad. Saludos!

Feb 8, 2020 · 1 like · 176 followers View post →

Dr Salah

@DrSalah_nephro · X

RT @edgarvlermamd: CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to curre…

Feb 8, 2020 · 21 shares · 297 followers View post →

Roberto Gutiérrez

@DrRobertoGuti · X

RT @edgarvlermamd: CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to curre…

Feb 7, 2020 · 21 shares · 783 followers View post →

Y

@y_psychologist · X

https://t.co/gEJ0sbYyOL アルブミン尿がある2型糖尿病患者において、カナグリフロジン100mgを投与した群はプラセボ群と比し心血管イベント、脳卒中リスクが低かった。

Feb 5, 2020 · 6 likes · 12,070 followers View post →

Kingston

@kianboy · X

RT @edgarvlermamd: CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to curre…

Feb 4, 2020 · 41 shares · 461 followers View post →

Drdevi kalyan mishra

@KalyanDevi · X

RT @edgarvlermamd: CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to curre…

Feb 3, 2020 · 41 shares · 1,179 followers View post →

Roberto Gutiérrez

@DrRobertoGuti · X

RT @edgarvlermamd: CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to curre…

Feb 3, 2020 · 41 shares · 783 followers View post →

Manuel Méndez

@mendez_bailon · X

RT @Diabetes_SEMI: Estudio CREDENCE https://t.co/cgTY41Vuno ▶️4401 pacientes con DM2 y ERC asignados a canagliflozina o placebo ▶️Paci…

Jan 30, 2020 · 11 shares · 7,785 followers View post →

Raúl Ibáñez

@roloboton · X

RT @Diabetes_SEMI: Estudio CREDENCE https://t.co/cgTY41Vuno ▶️4401 pacientes con DM2 y ERC asignados a canagliflozina o placebo ▶️Paci…

Jan 30, 2020 · 11 shares · 144 followers View post →

Marta Varas❣️

@VarasMayoral · X

RT @Diabetes_SEMI: Estudio CREDENCE https://t.co/cgTY41Vuno ▶️4401 pacientes con DM2 y ERC asignados a canagliflozina o placebo ▶️Paci…

Jan 30, 2020 · 11 shares · 297 followers View post →

Lorenzo Bertomeu

@ManuduManuel · X

RT @Diabetes_SEMI: Estudio CREDENCE https://t.co/cgTY41Vuno ▶️4401 pacientes con DM2 y ERC asignados a canagliflozina o placebo ▶️Paci…

Jan 29, 2020 · 11 shares · 3,594 followers View post →

Chema Fernandez

@chemachir · X

RT @Diabetes_SEMI: Estudio CREDENCE https://t.co/cgTY41Vuno ▶️4401 pacientes con DM2 y ERC asignados a canagliflozina o placebo ▶️Paci…

Jan 26, 2020 · 11 shares · 3,836 followers View post →

Ana Piera #JuntosEsMasFacil

@ana_apiecar · X

RT @Diabetes_SEMI: Estudio CREDENCE https://t.co/cgTY41Vuno ▶️4401 pacientes con DM2 y ERC asignados a canagliflozina o placebo ▶️Paci…

Jan 26, 2020 · 11 shares · 2,573 followers View post →

Javier Carrasco, PhD

@fjcarrascos · X

RT @Diabetes_SEMI: Estudio CREDENCE https://t.co/cgTY41Vuno ▶️4401 pacientes con DM2 y ERC asignados a canagliflozina o placebo ▶️Paci…

Jan 25, 2020 · 11 shares · 1,312 followers View post →

Lorenzo Bertomeu

@ManuduManuel · X

RT @Diabetes_SEMI: Estudio CREDENCE https://t.co/cgTY41Vuno ▶️4401 pacientes con DM2 y ERC asignados a canagliflozina o placebo ▶️Paci…

Jan 25, 2020 · 11 shares · 3,594 followers View post →

Ismael Said Criado

@ismaelsaid · X

RT @Diabetes_SEMI: Estudio CREDENCE https://t.co/cgTY41Vuno ▶️4401 pacientes con DM2 y ERC asignados a canagliflozina o placebo ▶️Paci…

Jan 25, 2020 · 11 shares · 4,778 followers View post →

Jose Carlos Arevalo

@joscarlor2 · X

RT @Diabetes_SEMI: Estudio CREDENCE https://t.co/cgTY41Vuno ▶️4401 pacientes con DM2 y ERC asignados a canagliflozina o placebo ▶️Paci…

Jan 25, 2020 · 11 shares · 762 followers View post →

ときヲ

@toki_wo_koe · X

#SGLT2阻害薬の腎アウトカムを主要評価項目とした初の大規模臨床試験。 #カナグリフロジンによる腎保護作用が示されました.( #CREDENCE試験) Volume 380:2295-2306 June 13, 2019 #Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://t.co/EXVGpWq3CF

Jan 17, 2020 · 2,580 followers View post →

Alketa Koroshi

@gjyshiketa · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/SE7STVv9hu

Jan 4, 2020 · 106 followers View post →

Chile717

@Chile7171 · X

RT @Physns1stWatch: Featured research includes: —Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin - Preliminary Repo…

Dec 24, 2019 · 1 share · 683 followers View post →

PhysiciansFirstWatch

@Physns1stWatch · X

Featured research includes: —Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin - Preliminary Report —Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy —Targeting Huntingtin Expression in Patients with Huntington’s Disease https://t.co/fTIJEbj0jT

Dec 24, 2019 · 3 likes · 1 share · 14,688 followers View post →

María Paula Alvarez

@mapaula_alvarez · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://t.co/FzSGMeoHhT

Nov 17, 2019 · 1 like View post →

pinacol

@pinacol · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. https://t.co/5KebpaN8yU #jsphcs2019

Nov 3, 2019 · 1 like · 1,615 followers View post →

UCL Discovery

@ucl_discovery · X

Open Access UCL Research: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://t.co/9SbnojdphF

Oct 24, 2019 · 2,523 followers View post →

ma⊿

@HClO8_m · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/xMYieHz8pJ

Oct 22, 2019 · 146 followers View post →

Franklin Loachamin

@FranLoachamin · X

RT @kniraz7: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM #CREDENCE sounds like a game-changer! https://t.co…

Oct 19, 2019 · 1 share · 4,887 followers View post →

LinkkWorld Medical

@Linkkworld · X

NEJM Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy 1 Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation 2 IMAGES IN CLINICAL MEDICINE Disseminated... https://t.co/jLngetLNAW

Oct 4, 2019 · 109 followers View post →

うどん

@udon_med · X

正解は、SGLT2阻害薬です。最近出された論文で、ここ最近ではSGLT2阻害薬がバンバン処方されてます。ただ、ケトアシドーシスになるという副作用も報告されているので注意が必要です。 Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019;380:2295-306

Sep 15, 2019 · 2 likes · 2,732 followers View post →

うどん

@udon_med · X

@mugitya_oisiiyo 今回のやつはこの論文ですね

Sep 14, 2019 · 2,732 followers View post →

Joan Atmetlla Andreu

@JoanAtmetllaA · X

RT @rincondesisifo: (Evid Based Med) Prevención de la enfermedad CV y el fallo renal con iSGLT2 en pac con DM2 https://t.co/LU0xgtHD4c REC…

Sep 12, 2019 · 11 shares · 186 followers View post →

Pilar Babi Rourera

@PRourera · X

RT @rincondesisifo: (Evid Based Med) Prevención de la enfermedad CV y el fallo renal con iSGLT2 en pac con DM2 https://t.co/LU0xgtHD4c REC…

Sep 12, 2019 · 11 shares · 298 followers View post →

Santiago M

@sntg70 · X

RT @rincondesisifo: (Evid Based Med) Prevención de la enfermedad CV y el fallo renal con iSGLT2 en pac con DM2 https://t.co/LU0xgtHD4c REC…

Sep 11, 2019 · 11 shares · 137 followers View post →

Aurora Rovira

@aurorarovira · X

RT @rincondesisifo: (Evid Based Med) Prevención de la enfermedad CV y el fallo renal con iSGLT2 en pac con DM2 https://t.co/LU0xgtHD4c REC…

Sep 10, 2019 · 11 shares · 369 followers View post →

Rosa Madridejos

@RosaMadridejos · X

RT @rincondesisifo: (Evid Based Med) Prevención de la enfermedad CV y el fallo renal con iSGLT2 en pac con DM2 https://t.co/LU0xgtHD4c REC…

Sep 10, 2019 · 11 shares · 496 followers View post →

Carmelo

@carmelprzrz · X

RT @rincondesisifo: (Evid Based Med) Prevención de la enfermedad CV y el fallo renal con iSGLT2 en pac con DM2 https://t.co/LU0xgtHD4c REC…

Sep 10, 2019 · 11 shares · 451 followers View post →

MarionaNadal

@manallo78 · X

RT @rincondesisifo: (Evid Based Med) Prevención de la enfermedad CV y el fallo renal con iSGLT2 en pac con DM2 https://t.co/LU0xgtHD4c REC…

Sep 10, 2019 · 11 shares · 386 followers View post →

SEFAP

@Sefap_FAP · X

RT @rincondesisifo: (Evid Based Med) Prevención de la enfermedad CV y el fallo renal con iSGLT2 en pac con DM2 https://t.co/LU0xgtHD4c REC…

Sep 10, 2019 · 11 shares · 7,949 followers View post →

Farmacia Madrid AP

@FarmaMadridAP · X

RT @rincondesisifo: (Evid Based Med) Prevención de la enfermedad CV y el fallo renal con iSGLT2 en pac con DM2 https://t.co/LU0xgtHD4c REC…

Sep 10, 2019 · 11 shares · 8,362 followers View post →

rincondesisifo

@rincondesisifo · X

(Evid Based Med) Prevención de la enfermedad CV y el fallo renal con iSGLT2 en pac con DM2 https://t.co/LU0xgtHD4c REC de ECA https://t.co/OESXN5cd3C Estudio original Y así lo vimos nosotros https://t.co/Jgl9lu8qpB https://t.co/IyvbrgFsCK

Sep 10, 2019 · 12 likes · 11 shares · 8,455 followers View post →

Miguel Angel Jimenez

@DrMJimenez · X

RT @NephJC: T-1 hour to the European #NephJC on the CREDENCE trial—Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. Hop…

Aug 22, 2019 · 8 shares · 1,972 followers View post →

David Mapletoft

@davidmapletoft · X

#RED2019 https://t.co/ues3azFM5x

Aug 19, 2019 · 204 followers View post →

NM Hospital Medicine

@NMHospMed · X

Want to learn more? #weeklyJClub Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/uQzYWrcoJZ

Aug 7, 2019 · 1 like · 700 followers View post →

織田病院薬剤師です

@odayuai_pharma · X

RT @RealTNagasawa: CREDENCE試験。腎予後を劇的に改善、カナグリフロジン群では血圧が-3.3mmHg、体重-0.8kgである事には注意。また人種構成は白人が65％強、アジア人が20％、黒人が5％（EMPA研究も似たような構成） Canagliflozin…

Aug 1, 2019 · 1 share · 485 followers View post →

長澤　将（腎臓内科医）

@RealTNagasawa · X

CREDENCE試験。腎予後を劇的に改善、カナグリフロジン群では血圧が-3.3mmHg、体重-0.8kgである事には注意。また人種構成は白人が65％強、アジア人が20％、黒人が5％（EMPA研究も似たような構成） Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/XraoCID16V

Jul 23, 2019 · 1 like · 1 share · 5,209 followers View post →

Fu Mei Sian

@meisian723 · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/SNXawYRk0v

Jul 15, 2019 · 1 like · 63 followers View post →

Sarada Tyson

@SaradaTyson · X

Just Released ...... Amazing info Perkovic, V. et al. (2019) ‘Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy’, New England Journal of Medicine. Massachusetts Medical Society, 380(24), pp. 2295–2306. doi: 10.1056/NEJMoa1811744.

Jul 9, 2019 · 1 like · 10 followers View post →

EvidenceAlerts

@EvidenceAlerts · X

#EBM EvidenceAlerts | Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. https://t.co/SFgX3WpCQh

Jul 9, 2019 · 3,553 followers View post →

SEFAP

@Sefap_FAP · X

(SIETES) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://t.co/EjYSLkmywX

Jul 9, 2019 · 7,949 followers View post →

NU Internal Medicine

@NU_IntMed · X

RT @kimche: This year we are starting @NU_IntMed EBMondays: Journal club on 1st Monday of each block.

Jul 8, 2019 · 1 share · 5,504 followers View post →

Cheryl Lee MD (She/Her)

@kimche · X

This year we are starting @NU_IntMed EBMondays: Journal club on 1st Monday of each block.

Jul 8, 2019 · 8 likes · 1 share · 939 followers View post →

Erik Rafflenbeul

@KardiologieHH · X

Amazing results and very well conducted trial: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/ELlOxqfY4l

Jul 4, 2019 · 8,715 followers View post →

Open Research at Aston

@Astonopenaccess · X

HEALTH Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://t.co/N4538fLdQi

Jul 4, 2019 · 745 followers View post →

renalRCTs

@renalRCTs · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. https://t.co/wmJshdyLGi

Jul 2, 2019 · 1 like · 39 followers View post →

Stanford Center for Clinical Research

@SCCR_Stanford · X

The Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (#CREDENCE) trial suggests that Canagliflozin provides renal & #CV protection in patients with #T2D with chronic kidney disease (#CKD). https://t.co/si2gJzvQvX

Jun 26, 2019 · 1,187 followers View post →

Rajkumar Doshi MD MPH FACC

@raj20490 · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/O8xMdiB3nH

Jun 26, 2019 · 1,036 followers View post →

Sharona Azriel

@SharonaAzriel · X

RT @cristinatejerap: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | ⁦@NEJM⁩ ⁦@diabeteSEEN⁩ https://t.co/TCjLzmenAw

Jun 18, 2019 · 6 shares · 1,405 followers View post →

Paola Villar S.

@LunarejaVillar · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/ttRbKLAHmR

Jun 18, 2019 · 7,628 followers View post →

Gabriel Gimenez MD

@ggimenezendocri · X

RT @ggimenezendocri: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/gBGAve1JRF sglt2 inhibitors sh…

Jun 17, 2019 · 1 share · 524 followers View post →

Rafa Gastro

@rafagastro · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM is this a class-effect or single related to cana? https://t.co/ASZ99t72MA

Jun 16, 2019 · 1,339 followers View post →

Dumont Audrey

@DumontAudrey6 · X

RT @NephroLeuven: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM - game changing class effects of the SGLT2 inh…

Jun 16, 2019 · 2 shares · 60 followers View post →

Beatriz Lardiés

@BeatrizLardies · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 14, 2019 · 17 shares · 777 followers View post →

Ana Sanchez Bao

@ana_sanchez_bao · X

RT @Foroactua: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | ⁦@NEJM⁩ ⁦@diabeteSEEN⁩ https://t.co/LZTPx3UdBl … https…

Jun 14, 2019 · 1 share · 1,092 followers View post →

Foroactua

@Foroactua · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | ⁦@NEJM⁩ ⁦@diabeteSEEN⁩ https://t.co/LZTPx3UdBl … https://t.co/0kvv6TcEYa https://t.co/gYa3L4CPiW

Jun 14, 2019 · 2 likes · 1 share · 1,154 followers View post →

Maria A. Real Lou

@mareallou · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/Xpb1xCLT4t

Jun 13, 2019 · 362 followers View post →

Lorenzo Bertomeu

@ManuduManuel · X

RT @cristinatejerap: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | ⁦@NEJM⁩ ⁦@diabeteSEEN⁩ https://t.co/TCjLzmenAw

Jun 13, 2019 · 6 shares · 3,594 followers View post →

Carls H. Eschneider

@Epi_centro_MAX · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 17 shares · 217 followers View post →

NephrologyLeuven

@NephroLeuven · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM - game changing class effects of the SGLT2 inhibitors! https://t.co/QVGM3rOaW8

Jun 13, 2019 · 7 likes · 2 shares · 740 followers View post →

Cristina Tejera

@cristinatejerap · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | ⁦@NEJM⁩ ⁦@diabeteSEEN⁩ https://t.co/TCjLzmenAw

Jun 13, 2019 · 13 likes · 6 shares · 11,471 followers View post →

lupe

@mapope60 · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 17 shares · 166 followers View post →

Anace Pastor ✨️ Renalis

@anace710 · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 17 shares · 1,899 followers View post →

Pilar Martínez

@amaryl_endo · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 17 shares · 61 followers View post →

Flor García

@florblue77 · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 17 shares · 738 followers View post →

David Palacios

@DrDPalacios · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 17 shares · 474 followers View post →

Sergio Hevia

@SerHevNav · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 17 shares · 722 followers View post →

Teresa Gijon Conde

@TGijonConde · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/4HX5Ds9Lga

Jun 13, 2019 · 1 like · 1,054 followers View post →

Adam Cifu

@adamcifu · X

SGLT2 inhibitors are on quite a roll... Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/lfoAhVJhLL

Jun 13, 2019 · 4 likes · 26,023 followers View post →

Luis Rguez. Padial

@luisrpadial · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 17 shares · 3,033 followers View post →

ねこまた見習い

@vc_neco · X

RT @codeblueflower: 利益相反があることがそんなに悪なのか？今週のNEJMの1本目、COI山盛りに書いてあるで。でもその論文自体が無価値にはならんでしょう。逆に「あるから」だけで切り捨てるのは読めなさすぎでは？ Canagliflozin and Renal…

Jun 13, 2019 · 5 shares · 3,453 followers View post →

しょくまじん

@shmajin · X

RT @codeblueflower: 利益相反があることがそんなに悪なのか？今週のNEJMの1本目、COI山盛りに書いてあるで。でもその論文自体が無価値にはならんでしょう。逆に「あるから」だけで切り捨てるのは読めなさすぎでは？ Canagliflozin and Renal…

Jun 13, 2019 · 5 shares · 1,113 followers View post →

Juanmarcosgg

@juanmarcosgg · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 17 shares · 510 followers View post →

SightGasm aka The Gaz

@sightgasm · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/D7wph1JH15

Jun 13, 2019 · 1 like · 2,889 followers View post →

Alberto More

@albmorepuccetti · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 17 shares · 131 followers View post →

Raquel Delgado

@RaquelD20061973 · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 17 shares · 123 followers View post →

Ｙkun

@yakkusoooooo · X

RT @codeblueflower: 利益相反があることがそんなに悪なのか？今週のNEJMの1本目、COI山盛りに書いてあるで。でもその論文自体が無価値にはならんでしょう。逆に「あるから」だけで切り捨てるのは読めなさすぎでは？ Canagliflozin and Renal…

Jun 13, 2019 · 5 shares · 299 followers View post →

Maria Jose Soler

@PepaSolerR · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 17 shares · 4,709 followers View post →

Eduardo Enriquez

@EnriquezEdwardo · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 17 shares · 760 followers View post →

Josean Alarcon

@josalar13 · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 17 shares · 917 followers View post →

Dr Jean Pierre Laroche #vacciné 6.0

@Echoraljpangio · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/248uh4IELf

Jun 13, 2019 · 2,714 followers View post →

Juan Carlos Obaya

@jcobaya69 · X

RT @almucastro01: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 17 shares · 858 followers View post →

Almudena Castro Conde

@almucastro01 · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/JnyEFye0qA

Jun 13, 2019 · 18 likes · 17 shares · 16,046 followers View post →

Patrick Holmes

@drpatrickholmes · X

RT @AmarPut: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/zqhPaxuMkp

Jun 13, 2019 · 1 share · 3,351 followers View post →

魔狸(35歳) ポケGoトレーナー台湾独立

@Matanuki · X

RT @codeblueflower: 利益相反があることがそんなに悪なのか？今週のNEJMの1本目、COI山盛りに書いてあるで。でもその論文自体が無価値にはならんでしょう。逆に「あるから」だけで切り捨てるのは読めなさすぎでは？ Canagliflozin and Renal…

Jun 13, 2019 · 5 shares · 2,168 followers View post →

まる

@standardtherap · X

RT @codeblueflower: 利益相反があることがそんなに悪なのか？今週のNEJMの1本目、COI山盛りに書いてあるで。でもその論文自体が無価値にはならんでしょう。逆に「あるから」だけで切り捨てるのは読めなさすぎでは？ Canagliflozin and Renal…

Jun 12, 2019 · 5 shares · 2,636 followers View post →

Eric Thervet

@EricThervet · X

@Perene9 Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/mz0qS1pJ7G

Jun 12, 2019 · 395 followers View post →

Jim Myers

@kidneystories · X

RT @PGee51: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/4NCH3woZoW

Jun 12, 2019 · 2 shares · 3,482 followers View post →

Patrick O. Gee, Ph.D. JLC

@PGee51 · X

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://t.co/4NCH3woZoW

Jun 11, 2019 · 3 likes · 2 shares · 889 followers View post →

Manuel Vazquez V

@ManuelVVidaurre · X

RT @docramiro: Esto para disminuir progresión de daño renal y riesgo cardiovascular. Esto por el estudio #CREDENCE donde se encontró reducc…

Jun 8, 2019 · 1 share · 277 followers View post →

Ramiro Esparza

@docramiro · X

Esto para disminuir progresión de daño renal y riesgo cardiovascular. Esto por el estudio #CREDENCE donde se encontró reducción de ambos en un 30% y 20% respectivamente. Link: https://t.co/oFjumkHWYe, https://t.co/zW1pbAngmZ https://t.co/bgFCyMqYgk

Jun 8, 2019 · 4 likes · 1 share · 68,413 followers View post →

David A. Cohen

@DavidACohen_MD · X

https://t.co/e0OIhmoUJB

Jun 5, 2019 · 1 like · 2,519 followers View post →

Neil Sutaria

@SutariaMD · X

@garyromakable @kidney_boy Awesome results with SLGT2, but risks of genital infections and euDKA are concerning (seen 3 SGLT2-induced euDKA). I’m a huge advocate but rx only if patient has excellent Endo follow up. https://t.co/wMbYFjwNfy

May 29, 2019 · 1 like · 164 followers View post →

Lorenzo Bertomeu

@ManuduManuel · X

RT @CristobMorales: https://t.co/hoyQNZCHH2 U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) for the Treatment of Chronic Kidne…

May 28, 2019 · 1 share · 3,594 followers View post →

Cristobal Morales

@CristobMorales · X

https://t.co/hoyQNZCHH2 U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/FsO9lwMPaP #CREDENCETrial https://t.co/p8kBfPuh62

May 27, 2019 · 6 likes · 1 share · 17,067 followers View post →

Flor García

@florblue77 · X

RT @redGDPS: Que nos dice el #CREDENCE en funciones renales <60% #SEDiab19 https://t.co/TLsun5LFqj https://t.co/rBSK0ziXzu

Apr 28, 2019 · 2 shares · 738 followers View post →

Raquel Faradji

@rfaradji · X

RT @redGDPS: Que nos dice el #CREDENCE en funciones renales <60% #SEDiab19 https://t.co/TLsun5LFqj https://t.co/rBSK0ziXzu

Apr 27, 2019 · 2 shares · 1,119 followers View post →

redGDPS Diabetes

@redGDPS · X

Que nos dice el #CREDENCE en funciones renales <60% #SEDiab19 https://t.co/TLsun5LFqj https://t.co/rBSK0ziXzu

Apr 26, 2019 · 2 likes · 2 shares · 15,521 followers View post →

khalid alhussain

@k_a_alhussain · X

RT @DRKAMALAYOUB: استخدام دواء ال canagliflozin في علاج داء السكري يخفض نسبة الاصابة بالفشل الكلوي بنسبة الثلث . https://t.co/JzzNtMrliS

Apr 16, 2019 · 4 shares · 4,156 followers View post →

Dr Ihab Suliman

@IhabFathiSulima · X

RT @DRKAMALAYOUB: استخدام دواء ال canagliflozin في علاج داء السكري يخفض نسبة الاصابة بالفشل الكلوي بنسبة الثلث . https://t.co/JzzNtMrliS

Apr 16, 2019 · 4 shares · 87,670 followers View post →

الدكتور كمال أيوب

@DRKAMALAYOUB · X

استخدام دواء ال canagliflozin في علاج داء السكري يخفض نسبة الاصابة بالفشل الكلوي بنسبة الثلث . https://t.co/JzzNtMrliS

Apr 15, 2019 · 4 likes · 4 shares · 23,784 followers View post →

Kenar Jhaveri, MD

@kdjhaveri.bsky.social · Bluesky

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa1811744#.XLPWBfhXvio.twitter

Apr 14, 2019 View post →

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

SGLT2 Inhibitors for Kidney Disease: Clinical Insights and Benefits

Impact of Salt Substitutes on Cardiovascular Health

Updates on Cardiological Research: Key Findings and Implications

Impact of SGLT2 Inhibitors on Kidney Health in Diabetes Patients